Skip to main content
. 2023 Dec 21;19(9):1877–1878. doi: 10.4103/1673-5374.391182

Figure 1.

Figure 1

Drug candidates targeting Aβ and/or tau or facilitating degradation via the ALP.

The drugs listed in the three circles are currently in clinical trials. The molecular tweezer CLR01 (Shahpasand-Kroner et al., 2023) in the middle has been shown preclinically to target all three mechanisms. Created using Adobe Illustrator. Aβ: Amyloid-β; ALP: autophagy-lysosomal pathway.